Seagen posts results of Phase 3 ECHELON-3 trial of brentuximab vedotin in relapsed/refractory DLBCL
The study enrolled 240 participants and compared brentuximab vedotin plus lenalidomide and rituximab to placebo plus lenalidomide and rituximab. Results were first posted on ClinicalTrials.gov on October 21, 2026.
Primary source
ClinicalTrials.gov results record, October 21, 2026
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Read the source: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation